NCT04781322View on ClinicalTrials.gov

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Alcohol Associated Liver DiseaseHeavy Drinking Behavior
Interventions
DRUG

Alirocumab

Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.

OTHER

Placebo

Heavy drinking healthy volunteers

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH